Paweletz C P, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta L A, Petricoin E F
Tissue Proteomics Unit, Division of Therapeutic Proteins, CBER, Food and Drug Administration, Bethesda, MD 20892, USA.
Dis Markers. 2001;17(4):301-7. doi: 10.1155/2001/674959.
Nipple aspirate fluid (NAF) has been used for many years as a potential non-invasive method to identify markers for breast cancer risk or early detection. Because individual markers have not been optimal, we are exploring the use of surface enhanced laser desorption and ionization time of flight (SELDI-TOF) mass spectrometry to identify patterns of proteins that might define a proteomic signature for breast cancer. SELDI-TOF was used to analyze a study set of NAF samples that included 12 women with breast cancer and 15 healthy controls (the latter included three women with an abnormal mammogram but subsequent normal biopsy). In this preliminary report, we present data showing that SELDI analysis of NAF is rapid, reproducible, and capable of identifying protein signatures that appear to differentiate NAF samples from breast cancer patients and healthy controls, including those with an abnormal mammogram who were later proven to be biopsy normal.
乳头抽吸液（NAF）多年来一直被用作一种潜在的非侵入性方法，以识别乳腺癌风险或早期检测的标志物。由于单个标志物并不理想，我们正在探索使用表面增强激光解吸电离飞行时间（SELDI-TOF）质谱法来识别可能定义乳腺癌蛋白质组学特征的蛋白质模式。SELDI-TOF用于分析一组NAF样本的研究集，其中包括12名乳腺癌女性和15名健康对照者（后者包括三名乳房X光检查异常但随后活检正常的女性）。在这份初步报告中，我们展示的数据表明，对NAF进行SELDI分析快速、可重复，并且能够识别出似乎能区分乳腺癌患者和健康对照者的NAF样本的蛋白质特征，包括那些乳房X光检查异常但后来活检证明正常的人。
